Goldman Sachs Group Inc Unity Biotechnology, Inc. Transaction History

Goldman Sachs Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	BUY	$0.4 - $4.27 $4,262 - $45,496	10,655 New	10,655 $4,000
Q3 2022 Nov 10, 2022	BUY	$0.4 - $4.27 $4,262 - $45,496	10,655 New	10,655 $0
Q2 2022 Aug 15, 2022	SELL	$0.56 - $1.29 $12,992 - $29,928	-23,200 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.72 - $1.86 $48,214 - $124,553	-66,964 Reduced 74.27%	23,200 $26,000
Q4 2021 Feb 14, 2022	BUY	$1.3 - $3.17 $63,027 - $153,691	48,483 Added 116.32%	90,164 $132,000
Q3 2021 Nov 10, 2021	BUY	$2.91 - $4.5 $121,291 - $187,564	41,681 New	41,681 $125,000

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $20.6M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.